

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS
ANNOUNCEMENT AND ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2021;
AND
(2) DATE OF BOARD MEETING**

Reference is made to the announcements of China NT Pharma Group Company Limited (the “**Company**”) dated 31 March 2022 and 4 April 2022 in relation to the unaudited annual results of the Company and its subsidiaries (together referred to as the “**Group**”) for the year ended 31 December 2021 (“**2021 Annual Results**”).

**DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS ANNOUNCEMENT
AND ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

The escalation of the COVID-19 pandemic control quarantine measures and restrictions on travel and logistics in Hong Kong and China have brought practical difficulties to the auditors of the Company in their audit work. The auditing process of the 2021 Annual Results has not yet been fully completed as at the date of this announcement owing to delay in the auditing process and additional time is required for the auditors of the Company to complete the auditing process including but not limited to, obtaining necessary supporting documents and confirmations from customers, suppliers and external parties of the Group.

Based on discussions with the auditor of the Company, the information currently available to the Company and the current auditing process progress, the Company expects to publish the audited 2021 Annual Results on Friday, 20 May 2022 and despatch the annual report of the Group for the financial year ended 31 December 2021 (the “**2021 Annual Report**”) to the shareholders of the Company on or before Tuesday, 31 May 2022.

In compliance with the “Frequently asked questions on the Joint Statement in relation to Results Announcements in light of Travel Restrictions related to the Severe Respiratory Disease associated with a Novel Infectious Agent (Joint Statement) and Holding of General Meetings” issued by the Securities and Futures Commission of Hong Kong and the Stock Exchange and last updated on 8 April 2022, an application has been made to the Stock Exchange on 6 May 2022 for approval of the further delay in publication of the audited 2021 Annual Results and 2021 Annual Report and waiver of the Company’s strict compliance of the relevant requirement under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to the publication of the audited 2021 Annual Results and 2021 Annual Report. As such, the further delay of publication of the audited 2021 Annual Results and 2021 Annual Report is subject to the approval to be given by the Stock Exchange.

Further announcement(s) will be made by the Company as and when necessary.

DATE OF BOARD MEETING

In view of this, the board of directors of the Company (the “**Board**”) announces that a meeting of the Board for the purpose of considering and approving, among other matters, the audited 2021 Annual Results and its publication will be held on Friday, 20 May 2022.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 6 May 2022

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.